News | Brachytherapy Systems | April 18, 2019

New study evaluated combination of maximum safe resection with surgically-guided collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms

Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms

April 18, 2019 — Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on surgically targeted radiation therapy for previously irradiated intracranial neoplasms during the 2019 American Association of Neurological Surgeons (AANS) annual scientific meeting, April 13-17 in San Diego. Nakaji’s research was the winner of the Mahaley Clinical Research Award.

Resection alone is typically insufficient for recurrent, previously irradiated intracranial neoplasms and repeat adjuvant external beam radiation treatment (EBRT) is often contraindicated. For these reasons, researchers prospectively evaluated the combination of maximum safe resection (R) and surgically guided collagen tile brachytherapy (TBT) in this cohort of patients. This study differed from older studies in that the isotope used, Cesium 131, has a shorter half-life than that used a generation ago, and the brachytherapy seed spacing is achieved by imbedding the sources in a collagen carrier.

According to researchers, "We believe that this new technology is fundamentally different from the older brachytherapy studies in both the isotope and the spacing, and this is what has given us our favorable results across a range of tumor types.”

At the end of the study, it was found that surgically targeted tile brachytherapy exhibited good site local control (LC) and overall survival (OS) with complication rates comparable to existing treatments. This study adds to recent studies supporting the use of brachytherapy for neurosurgical disease. This treatment could expand the therapeutic options for this difficult cohort of patients.

For more information: www.aans.org

Related Content

News | Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

Time August 05, 2022
arrow
Feature | Oncology Information Management Systems (OIMS)

August 2, 2022 — The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to ...

Time August 02, 2022
arrow
News | Nuclear Imaging

July 27, 2022 — Patients for Safer Nuclear Medicine, a coalition of 29 patient advocacy organizations representing ...

Time July 27, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

July 27, 2022 — Multitasking is not just an office skill. It’s key to functioning as a human, and it involves something ...

Time July 27, 2022
arrow
News | Radiation Oncology

July 25, 2022 — RaySearch Laboratories AB announces the launch of RayStation* 12A, the latest version of the company’s ...

Time July 25, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

July 25, 2022 — For any drug to be successful in treating mental health or neurological problems, the medicine has to ...

Time July 25, 2022
arrow
News | PET Imaging

July 20, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 20, 2022
arrow
News | Radiopharmaceuticals and Tracers

July 20, 2022 — -NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 20, 2022
arrow
News | Artificial Intelligence

July 20, 2022 — Whiterabbit.ai, an AI company targeting late-stage diseases, today announced efforts to recruit ...

Time July 20, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

July 19, 2022 — Hebrew University of Jerusalem (HU) researchers have developed an early-stage diagnosis of Parkinson’s ...

Time July 19, 2022
arrow
Subscribe Now